Jaroslav Roh

Dr. Jaroslav Roh


Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 August 2012 in European Journal of Organic Chemistry
Verified
Journal Article
Closed access
PDF file
JRJaroslav Roh
Jaroslav Roh
KVKaterina Vavrova
Katerina Vavrova
AHAlexandr Hrabálek
Alexandr Hrabálek

6 December 2013 in Langmuir
Verified
Journal Article
Closed access
BŠBarbora Školová
Barbora Školová
BJBarbora Janůšová
Barbora Janůšová
Jarmila ZbytovskaJarmila Zbytovska
Jarmila Zbytovska
GGGert Gooris
Gert Gooris
JBJoke Bouwstra
Joke Bouwstra
KVKaterina Vavrova
Katerina Vavrova

21 November 2022 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
VFVladimir Finger
Vladimir Finger
MKMartin Kufa
Martin Kufa
OSOndrej Soukup
Ondrej Soukup
DCDaniele Castagnolo
Daniele Castagnolo
JRJaroslav Roh
Jaroslav Roh
Jan KorabecnyJan Korabecny
Jan Korabecny

15 March 2016 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
GKGalina Karabanovich
Galina Karabanovich
JZJúlia Zemanová
Júlia Zemanová
TSTomáš Smutný
Tomáš Smutný
RSRita Székely
Rita Székely
MŠMichal Šarkan
Michal Šarkan
JRJaroslav Roh
Jaroslav Roh

21 August 2014 in The Journal of Physical Chemistry B
Verified
Journal Article
Closed access
BŠBarbora Školová
Barbora Školová
KHKlára Hudská
Klára Hudská
PPPetra Pullmannová
Petra Pullmannová
AKAndrej Kováčik
Andrej Kováčik
KPKarel Palát
Karel Palát
KVKaterina Vavrova
Katerina Vavrova

1 November 2021 in Circulation: Heart Failure
Verified
Journal Article
Closed access
PDF file
EJEduard Jirkovský
Eduard Jirkovský
AJAnna Jirkovská
Anna Jirkovská
HBHana Bavlovič-Piskáčková
Hana Bavlovič-Piskáčková
VSVeronika Skalická
Veronika Skalická
ZPZuzana Pokorná
Zuzana Pokorná
MSMartin Sterba
Martin Sterba
Background: Anthracycline-induced heart failure has been traditionally attributed to direct iron-catalyzed oxidative damage. Dexrazoxane (DEX)—the only drug approved for its prevention—has been believed to protect the heart via its iron-chelating metabolite ADR-925. However, direct evidence is lacking, and recently proposed TOP2B (topoisomerase II beta) hypothesis challenged the original concept. Methods: Pharmacokinetically guided study of the cardioprotective effects of clinically used DEX and its chelating metabolite ADR-925 (administered exogenously) was performed together with mechanistic experiments. The cardiotoxicity was induced by daunorubicin in neonatal ventricular cardiomyocytes in vitro and in a chronic rabbit model in vivo (n=50). Results: Intracellular concentrations of ADR-925 in neonatal ventricular cardiomyocytes and rabbit hearts after treatment with exogenous ADR-925 were similar or exceeded those observed after treatment with the parent DEX. However, ADR-925 did not protect neonatal ventricular cardiomyocytes against anthracycline toxicity, whereas DEX exhibited significant protective effects (10–100 µmol/L; P <0.001). Unlike DEX, ADR-925 also had no significant impact on daunorubicin-induced mortality, blood congestion, and biochemical and functional markers of cardiac dysfunction in vivo (eg, end point left ventricular fractional shortening was 32.3±14.7%, 33.5±4.8%, 42.7±1.0%, and 41.5±1.1% for the daunorubicin, ADR-925 [120 mg/kg]+daunorubicin, DEX [60 mg/kg]+daunorubicin, and control groups, respectively; P <0.05). DEX, but not ADR-925, inhibited and depleted TOP2B and prevented daunorubicin-induced genotoxic damage. TOP2B dependency of the cardioprotective effects was probed and supported by experiments with diastereomers of a new DEX derivative. Conclusions: This study strongly supports a new mechanistic paradigm that attributes clinically effective cardioprotection against anthracycline cardiotoxicity to interactions with TOP2B but not metal chelation and protection against direct oxidative damage.